Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250


Erratum for Ramakrishnan et al., "Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21".

Ramakrishnan A, Schumack NM, Gariepy CL, Eggleston H, Nunez G, Espinoza N, Nieto M, Castillo R, Rojas J, McCoy AJ, Beck Z, Matyas GR, Alving CR, Guerry P, Poly F, Laird RM.

mSphere. 2019 Jun 26;4(3). pii: e00440-19. doi: 10.1128/mSphere.00440-19. No abstract available.


Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).

Cawlfield A, Genito CJ, Beck Z, Bergmann-Leitner ES, Bitzer AA, Soto K, Zou X, Hadiwidjojo SH, Gerbasi RV, Mullins AB, Noe A, Waters NC, Alving CR, Matyas GR, Dutta S.

Vaccine. 2019 Jun 27;37(29):3793-3803. doi: 10.1016/j.vaccine.2019.05.059. Epub 2019 May 28.


Correction for Ramakrishnan et al., "Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21".

Ramakrishnan A, Schumack NM, Gariepy CL, Eggleston H, Nunez G, Espinoza N, Nieto M, Castillo R, Rojas J, McCoy AJ, Beck Z, Matyas GR, Alving CR, Guerry P, Poly F, Laird RM.

mSphere. 2019 May 22;4(3). pii: e00351-19. doi: 10.1128/mSphere.00351-19. No abstract available.


Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21.

Ramakrishnan A, Schumack NM, Gariepy CL, Eggleston H, Nunez G, Espinoza N, Nieto M, Castillo R, Rojas J, McCoy AJ, Beck Z, Matyas GR, Alving CR, Guerry P, Poly F, Laird RM.

mSphere. 2019 May 1;4(3). pii: e00101-19. doi: 10.1128/mSphere.00101-19. Erratum in: mSphere. 2019 May 22;4(3):. mSphere. 2019 Jun 26;4(3):.


Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.

Lakhal-Naouar I, Koles N, Rao M, Morrison EB, Childs JM, Alving CR, Aronson NE.

Vaccine. 2019 Jan 14;37(3):516-523. doi: 10.1016/j.vaccine.2018.11.052. Epub 2018 Dec 6.


Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition.

Singh P, Beck Z, Matyas GR, Alving CR.

J Liposome Res. 2019 Sep;29(3):247-250. doi: 10.1080/08982104.2018.1538239. Epub 2018 Nov 23.


Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans.

Rao M, Onkar S, Peachman KK, White Y, Trinh HV, Jobe O, Zhou Y, Dawson P, Eller MA, Matyas GR, Alving CR.

J Infect Dis. 2018 Oct 5;218(10):1541-1550. doi: 10.1093/infdis/jiy348.


A rapid solution-based method for determining the affinity of heroin hapten-induced antibodies to heroin, its metabolites, and other opioids.

Torres OB, Duval AJ, Sulima A, Antoline JFG, Jacobson AE, Rice KC, Alving CR, Matyas GR.

Anal Bioanal Chem. 2018 Jun;410(16):3885-3903. doi: 10.1007/s00216-018-1060-4. Epub 2018 Apr 19.


Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.

Beck Z, Torres OB, Matyas GR, Lanar DE, Alving CR.

J Control Release. 2018 Apr 10;275:12-19. doi: 10.1016/j.jconrel.2018.02.006. Epub 2018 Feb 9.


Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant.

Torres OB, Matyas GR, Rao M, Peachman KK, Jalah R, Beck Z, Michael NL, Rice KC, Jacobson AE, Alving CR.

NPJ Vaccines. 2017 May 2;2:13. doi: 10.1038/s41541-017-0013-9. eCollection 2017.


A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse.

Sulima A, Jalah R, Antoline JFG, Torres OB, Imler GH, Deschamps JR, Beck Z, Alving CR, Jacobson AE, Rice KC, Matyas GR.

J Med Chem. 2018 Jan 11;61(1):329-343. doi: 10.1021/acs.jmedchem.7b01427. Epub 2017 Dec 29.


Human Primary Macrophages Derived In Vitro from Circulating Monocytes Comprise Adherent and Non-Adherent Subsets with Differential Expression of Siglec-1 and CD4 and Permissiveness to HIV-1 Infection.

Jobe O, Kim J, Tycksen E, Onkar S, Michael NL, Alving CR, Rao M.

Front Immunol. 2017 Oct 23;8:1352. doi: 10.3389/fimmu.2017.01352. eCollection 2017.


Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.

Genito CJ, Beck Z, Phares TW, Kalle F, Limbach KJ, Stefaniak ME, Patterson NB, Bergmann-Leitner ES, Waters NC, Matyas GR, Alving CR, Dutta S.

Vaccine. 2017 Jul 5;35(31):3865-3874. doi: 10.1016/j.vaccine.2017.05.070. Epub 2017 Jun 7.


Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.

Seth L, Bingham Ferlez KM, Kaba SA, Musser DM, Emadi S, Matyas GR, Beck Z, Alving CR, Burkhard P, Lanar DE.

Vaccine. 2017 Oct 4;35(41):5448-5454. doi: 10.1016/j.vaccine.2017.02.040. Epub 2017 Mar 6.


Adjuvants for HIV vaccines.

Rao M, Alving CR.

Curr Opin HIV AIDS. 2016 Nov;11(6):585-592. Review.


Synthesis of Hapten-Protein Conjugate Vaccines with Reproducible Hapten Densities.

Torres OB, Alving CR, Matyas GR.

Methods Mol Biol. 2016;1403:695-710. doi: 10.1007/978-1-4939-3387-7_39.


Liposomal adjuvants for human vaccines.

Alving CR, Beck Z, Matyas GR, Rao M.

Expert Opin Drug Deliv. 2016 Jun;13(6):807-16. doi: 10.1517/17425247.2016.1151871. Epub 2016 Feb 25. Review.


A simple nonradioactive method for the determination of the binding affinities of antibodies induced by hapten bioconjugates for drugs of abuse.

Torres OB, Antoline JF, Li F, Jalah R, Jacobson AE, Rice KC, Alving CR, Matyas GR.

Anal Bioanal Chem. 2016 Feb;408(4):1191-204. doi: 10.1007/s00216-015-9223-z. Epub 2015 Dec 16.


Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte-derived macrophages: the importance of HIV-1 envelope V1V2 region.

Jobe O, Trinh HV, Kim J, Alsalmi W, Tovanabutra S, Ehrenberg PK, Peachman KK, Gao G, Thomas R, Kim JH, Michael NL, Alving CR, Rao VB, Rao M.

J Leukoc Biol. 2016 Jun;99(6):1089-106. doi: 10.1189/jlb.2A0815-361R. Epub 2015 Dec 14.


Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.

Peachman KK, Karasavvas N, Chenine AL, McLinden R, Rerks-Ngarm S, Jaranit K, Nitayaphan S, Pitisuttithum P, Tovanabutra S, Zolla-Pazner S, Michael NL, Kim JH, Alving CR, Rao M.

PLoS One. 2015 Dec 1;10(12):e0143895. doi: 10.1371/journal.pone.0143895. eCollection 2015.


Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.

Beck Z, Matyas GR, Jalah R, Rao M, Polonis VR, Alving CR.

Vaccine. 2015 Oct 13;33(42):5578-5587. doi: 10.1016/j.vaccine.2015.09.001. Epub 2015 Sep 13.


TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1.

Allam A, Majji S, Peachman K, Jagodzinski L, Kim J, Ratto-Kim S, Wijayalath W, Merbah M, Kim JH, Michael NL, Alving CR, Casares S, Rao M.

Sci Rep. 2015 Jun 2;5:10443. doi: 10.1038/srep10443.


Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Wieczorek L, Krebs SJ, Kalyanaraman V, Whitney S, Tovanabutra S, Moscoso CG, Sanders-Buell E, Williams C, Slike B, Molnar S, Dussupt V, Alam SM, Chenine AL, Tong T, Hill EL, Liao HX, Hoelscher M, Maboko L, Zolla-Pazner S, Haynes BF, Pensiero M, McCutchan F, Malek-Salehi S, Cheng RH, Robb ML, VanCott T, Michael NL, Marovich MA, Alving CR, Matyas GR, Rao M, Polonis VR.

J Virol. 2015 Aug;89(15):7478-93. doi: 10.1128/JVI.00412-15. Epub 2015 May 13.


Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Jalah R, Torres OB, Mayorov AV, Li F, Antoline JF, Jacobson AE, Rice KC, Deschamps JR, Beck Z, Alving CR, Matyas GR.

Bioconjug Chem. 2015 Jun 17;26(6):1041-53. doi: 10.1021/acs.bioconjchem.5b00085. Epub 2015 Jun 5.


Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate.

Beck Z, Matyas GR, Alving CR.

Biochim Biophys Acta. 2015 Mar;1848(3):775-80. doi: 10.1016/j.bbamem.2014.12.005. Epub 2014 Dec 12.


Isolation and purification of proteasomes from primary cells.

Steers NJ, Peachman KK, Alving CR, Rao M.

Curr Protoc Immunol. 2014 Nov 3;107:16.4.1-20. doi: 10.1002/0471142735.im1604s107. Review.


Adjuvants for vaccines to drugs of abuse and addiction.

Alving CR, Matyas GR, Torres O, Jalah R, Beck Z.

Vaccine. 2014 Sep 22;32(42):5382-9. doi: 10.1016/j.vaccine.2014.07.085. Epub 2014 Aug 8. Review.


Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines.

Torres OB, Jalah R, Rice KC, Li F, Antoline JF, Iyer MR, Jacobson AE, Boutaghou MN, Alving CR, Matyas GR.

Anal Bioanal Chem. 2014 Sep;406(24):5927-37. doi: 10.1007/s00216-014-8035-x. Epub 2014 Aug 2.


Synthesis and immunological effects of heroin vaccines.

Li F, Cheng K, Antoline JF, Iyer MR, Matyas GR, Torres OB, Jalah R, Beck Z, Alving CR, Parrish DA, Deschamps JR, Jacobson AE, Rice KC.

Org Biomol Chem. 2014 Oct 7;12(37):7211-32. doi: 10.1039/c4ob01053a.


Designing the epitope flanking regions for optimal generation of CTL epitopes.

Steers NJ, Currier JR, Jobe O, Tovanabutra S, Ratto-Kim S, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M.

Vaccine. 2014 Jun 12;32(28):3509-16. doi: 10.1016/j.vaccine.2014.04.039. Epub 2014 May 2.


Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine.

Matyas GR, Rice KC, Cheng K, Li F, Antoline JF, Iyer MR, Jacobson AE, Mayorov AV, Beck Z, Torres OB, Alving CR.

Vaccine. 2014 Mar 14;32(13):1473-9. doi: 10.1016/j.vaccine.2014.01.028. Epub 2014 Jan 28.


Platelets and erythrocyte-bound platelets bind infectious HIV-1 in plasma of chronically infected patients.

Beck Z, Jagodzinski LL, Eller MA, Thelian D, Matyas GR, Kunz AN, Alving CR.

PLoS One. 2013 Nov 25;8(11):e81002. doi: 10.1371/journal.pone.0081002. eCollection 2013.


HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.

Rao M, Peachman KK, Kim J, Gao G, Alving CR, Michael NL, Rao VB.

Curr HIV Res. 2013 Jul;11(5):427-38.


Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.

Matyas GR, Mayorov AV, Rice KC, Jacobson AE, Cheng K, Iyer MR, Li F, Beck Z, Janda KD, Alving CR.

Vaccine. 2013 Jun 10;31(26):2804-10. doi: 10.1016/j.vaccine.2013.04.027. Epub 2013 Apr 23.


Designing a soluble near full-length HIV-1 gp41 trimer.

Gao G, Wieczorek L, Peachman KK, Polonis VR, Alving CR, Rao M, Rao VB.

J Biol Chem. 2013 Jan 4;288(1):234-46. doi: 10.1074/jbc.M112.424432. Epub 2012 Nov 26.


HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses.

Steers NJ, Ratto-Kim S, de Souza MS, Currier JR, Kim JH, Michael NL, Alving CR, Rao M.

PLoS One. 2012;7(8):e42579. doi: 10.1371/journal.pone.0042579. Epub 2012 Aug 6.


Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.

Alving CR, Rao M, Steers NJ, Matyas GR, Mayorov AV.

Expert Rev Vaccines. 2012 Jun;11(6):733-44. doi: 10.1586/erv.12.35. Review.


An anti-phosphoinositide-specific monoclonal antibody that neutralizes HIV-1 infection of human monocyte-derived macrophages.

Jobe O, Peachman KK, Matyas GR, Asher LV, Alving CR, Rao M.

Virology. 2012 Sep 1;430(2):110-9. doi: 10.1016/j.virol.2012.04.017. Epub 2012 May 26.


Adjuvants for human vaccines.

Alving CR, Peachman KK, Rao M, Reed SG.

Curr Opin Immunol. 2012 Jun;24(3):310-5. doi: 10.1016/j.coi.2012.03.008. Epub 2012 Apr 19. Review.


Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide.

Zollinger WD, Babcock JG, Moran EE, Brandt BL, Matyas GR, Wassef NM, Alving CR.

Vaccine. 2012 Jan 17;30(4):712-21. doi: 10.1016/j.vaccine.2011.11.084. Epub 2011 Dec 3.


Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.

Peachman KK, Li Q, Matyas GR, Shivachandra SB, Lovchik J, Lyons RC, Alving CR, Rao VB, Rao M.

Clin Vaccine Immunol. 2012 Jan;19(1):11-6. doi: 10.1128/CVI.05376-11. Epub 2011 Nov 16.


Liposomes containing glucosyl ceramide specifically bind T4 bacteriophage: a self-assembling nanocarrier formulation.

Alving CR, Rao M, Peachman KK, Asher L, Rao VB.

J Liposome Res. 2011 Dec;21(4):279-85. doi: 10.3109/08982104.2011.559646. Epub 2011 Mar 14.


Infection of human peripheral blood mononuclear cells by erythrocyte-bound HIV-1: effects of antibodies and complement.

Beck Z, Brown BK, Matyas GR, Polonis VR, Rao M, Alving CR.

Virology. 2011 Apr 10;412(2):441-7. doi: 10.1016/j.virol.2011.01.037. Epub 2011 Feb 21.


The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization.

Peachman KK, Wieczorek L, Matyas GR, Polonis VR, Alving CR, Rao M.

Viral Immunol. 2010 Dec;23(6):627-32. doi: 10.1089/vim.2010.0061.


Highly effective generic adjuvant systems for orphan or poverty-related vaccines.

Rao M, Peachman KK, Li Q, Matyas GR, Shivachandra SB, Borschel R, Morthole VI, Fernandez-Prada C, Alving CR, Rao VB.

Vaccine. 2011 Jan 29;29(5):873-7. doi: 10.1016/j.vaccine.2010.11.049. Epub 2010 Nov 27.


Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire.

Steers NJ, Currier JR, Kijak GH, di Targiani RC, Saxena A, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M.

J Virol. 2011 Feb;85(4):1541-53. doi: 10.1128/JVI.01790-10. Epub 2010 Nov 24.


Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of β-chemokines.

Matyas GR, Wieczorek L, Bansal D, Chenine AL, Sanders-Buell E, Tovanabutra S, Kim JH, Polonis V, Alving CR.

Biochem Biophys Res Commun. 2010 Nov 26;402(4):808-12. doi: 10.1016/j.bbrc.2010.10.124. Epub 2010 Oct 30.


The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies.

Peachman KK, Wieczorek L, Polonis VR, Alving CR, Rao M.

Virology. 2010 Dec 20;408(2):213-23. doi: 10.1016/j.virol.2010.09.029. Epub 2010 Oct 20.


Human erythrocytes selectively bind and enrich infectious HIV-1 virions.

Beck Z, Brown BK, Wieczorek L, Peachman KK, Matyas GR, Polonis VR, Rao M, Alving CR.

PLoS One. 2009 Dec 14;4(12):e8297. doi: 10.1371/journal.pone.0008297.

Supplemental Content

Loading ...
Support Center